Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.34 |
| ▸ | CPB1 | P15086 | 7/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 5/20 | 0.33 |
| ▸ | GRB2 | P62993 | 1/20 | 0.33 |
| ▸ | ALPI | P09923 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28141560 | 0.83 | CPB2 (0.39) | CPB2CPB1 | |
| SCHEMBL10108842 | 0.79 | CYP1A2 (0.41) | CYP1A2CPB2CPB1SLC1A3TYR | |
| SCHEMBL13601990 | 0.78 | CYP1A2 (0.38) | CYP1A2CPB2CPB1SLC1A3ALPI | |
| SCHEMBL17224471 | 0.77 | CYP1A2 (0.44) | CYP1A2CPB2CPB1SLC1A3TYR | |
| SCHEMBL14798187 | 0.75 | CYP1A2 (0.45) | CYP1A2CPB2CPB1SLC1A3TYR | |
| SCHEMBL60911 | 0.75 | CYP1A2 (0.45) | CYP1A2CPB2CPB1SLC1A3TYR | |
| SCHEMBL6773700 | 0.75 | SIRT2 (0.49) | CYP1A2CPB2CPB1ALPIPKM | |
| SCHEMBL3839522 | 0.75 | SIRT2 (0.49) | CYP1A2CPB2CPB1ALPIPKM | |
| SCHEMBL21690129 | 0.75 | SIRT2 (0.49) | CYP1A2CPB2CPB1ALPIPKM | |
| Hydrochloric Acid SCHEMBL6697015 | 0.74 | TYR (0.45) | CYP1A2CPB2CPB1SLC1A3TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238057-B2 | Method for treating ocular neovascularization | NOVARTIS AG (CH) | 2016-01-19 | — | — | US | disclosed |
| US-20130165503-A1 | Method for Treating Ocular Neovascularization | NOVARTIS AG (CH) | 2013-06-27 | — | — | US | disclosed |
| US-8338384-B2 | Method for treating ocular neovascularization | NOVARTIS AG (CH) | 2012-12-25 | — | — | US | disclosed |
| EP-1401480-B1 | VIRAL VECTORS ENCODING ENDOSTATIN IN THE TREATMENT OF OCULAR NEOVASCULARIZATION | NOVARTIS AG (CH) | 2012-11-28 | — | — | EP | disclosed |
| US-20100286253-A1 | Method for treating ocular neovascularization | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| EP-1534751-B1 | OCULAR GENE THERAPY | NOVARTIS AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| CN-101637611-A | Ocular gene therapy | NOVARTIS AG CH | 2010-02-03 | — | — | CN | disclosed |
| US-20070104684-A1 | Ocular gene therapy | WELLSTAT OPHTHALMICS CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20060251621-A1 | Ocular gene therapy | NOVARTIS AG (CH) | 2006-11-09 | — | — | US | disclosed |
| EP-1534751-A2 | OCULAR GENE THERAPY | Novartis AG (CH) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004028635-A1 | OCULAR GENE THERAPY | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | disclosed |
| EP-1401480-A2 | USE OF ENDOSTATIN IN THE TREATMENT OF OCULAR NEOVASCULARIZATION | Novartis AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| WO-2004020469-A2 | OCULAR GENE THERAPY | NOVARTIS AG (CH) | 2004-03-11 | — | — | WO | disclosed |
| US-20020183253-A1 | Method of treating ocular neovascularization | WELLSTAT OPHTHALMICS CORPORATION | 2002-12-05 | — | — | US | disclosed |
| WO-2002067971-A2 | USE OF ENDOSTATIN IN THE TREATMENT OF OCULAR NEOVASCULARIZATION | NOVARTIS AG (CH) | 2002-09-06 | — | — | WO | disclosed |